<DOC>
	<DOCNO>NCT00003327</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient recurrent refractory head neck cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Recurrent Refractory Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate paclitaxel salvage therapy patient recurrent refractory head neck cancer . II . Evaluate safety paclitaxel patient population . III . Assess overall survival quality life patient . OUTLINE : This open label , multicenter , nonrandomized study . Patients receive intravenous paclitaxel 1 hour weekly . Each course consist four week . Patients receive treatment disease progression unacceptable toxic effect observe . Patients follow every 2 month first year , every 4 month completion treatment , every 3 month death . Patients complete quality life questionnaire prior first 6 course , every 2 course thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory head neck cancer Measurable evaluable disease At least one prior chemotherapy regimen recurrent metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Renal : Creatinine great 2 time ULN Calcium within normal limit Cardiovascular : No New York Heart Association class IIIIV heart disease No myocardial infarction within 6 month No congestive heart failure No unstable angina No clinically significant pericardial effusion arrhythmias Neurologic : No peripheral neuropathy great grade 1 Other : Not pregnant nursing Fertile patient must use effective contraceptive method Negative pregnancy test No active infection serious underlie medical condition No history hypersensitivity drug contain Cremophor ( teniposide , cyclosporine , vitamin K ) No prior invasive malignancy within past 2 year , except : Curatively treat basal squamous cell carcinoma skin Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 5 week since prior nitrosoureas , melphalan , mitomycin At least 3 week since prior chemotherapy Prior taxane therapy allow administer 3 week great schedule No concurrent chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy Concurrent megestrol ( Megace ) allow No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy great 30 % bone marrow No concurrent radiotherapy Surgery : At least 3 week since major surgery Other : At least 1 week since prior parenteral antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>stage IV lip oral cavity cancer</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage IV laryngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>stage IV paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
</DOC>